Erlotinib Active Not Recruiting Phase 2 Trials for EGFR NP_005219.2:p.L858R / Stage IV Non-Small Cell Lung Cancer / EGFR Activating Mutation / Non-Squamous Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer AJCC v7 / EGFR Exon 19 Deletion Mutation Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01532089Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations